Skip to Content
 

News: Melanoma

Melanoma study finds new way to enhance targeted therapies

Friday, March 10th, 2017

With the help of a drug formerly used to treat HIV/AIDS, researchers at Vanderbilt University Medical Center (VUMC) have found a way to make melanoma cells more vulnerable to targeted anti-cancer therapy. Since the AIDS drug is already FDA approved, clinical testing in melanoma patients could potentially begin sooner than if it was a novel […]

Award spurs Jonna’s research on ocular melanoma

Thursday, December 8th, 2016

Gowtham Jonna, M.D., senior retina fellow at the Vanderbilt Eye Institute, recently received a VitreoRetinal Surgery Foundation (VRSF) Research Award. Gowtham Jonna, M.D. The purpose of the award is to support young investigators conducting research on macular and retinal disease and to encourage a career devoted to retinal disease and research. Jonna is working on […]

VA honors Richmond’s scientific contributions

Thursday, October 6th, 2016

Vanderbilt University cancer researcher Ann Richmond, Ph.D., has won the 2016 William S. Middleton Award, the highest honor for scientific achievement bestowed by the Biomedical Laboratory Research and Development Service of the U.S. Department of Veterans Affairs (VA). Richmond is Ingram Professor of Cancer Research and professor of Cancer Biology and Medicine at Vanderbilt University […]

Precision medicine already changing cancer treatment strategies

Thursday, May 26th, 2016

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. “Nationwide we’re seeing great promise with this approach […]

Cancer Center patients make their musical dreams come true

Monday, May 16th, 2016

Rob Schieber and Jordan Lawhead each moved to Nashville to pursue a career in music. Songwriter and publisher Kris Bergsnes introduced them knowing they were both cancer survivors. But a chance meeting in a patient waiting room at Vanderbilt-Ingram Cancer Center (VICC) united the two men in their cancer journey as well as in friendship […]

Public invited to learn about VICC precision cancer medicine

Friday, April 29th, 2016

Leading cancer investigators from Vanderbilt-Ingram Cancer Center will unveil the latest in cancer research during an upcoming community event. “Precision Medicine in Cancer: At the Crossroads of Research and Treatment for Patients” will be held Tuesday, May 10, from 5:30 to 7:30 p.m. at the Vanderbilt Student Life Center, 310 25th Ave. S. The public is […]

Melanoma response to immune therapy

Friday, March 4th, 2016

Anti-PD-1 therapy – a treatment that stimulates the immune system to attack tumors – produces responses in up to 40 percent of melanoma patients. Predictive markers of response are needed to optimize patient selection, improve treatment decision-making and minimize costs. Justin Balko, Pharm.D., Ph.D., Douglas Johnson, M.D., and colleagues hypothesized that tumor expression of MHC-I […]

Combining treatments for melanoma

Monday, February 22nd, 2016

Chemotherapy and targeted anti-cancer drugs can induce tumor cell senescence. Although cell proliferation is shut down in senescent cells, there is enhanced expression of secreted factors that may promote or suppress tumor growth. Anna Vilgelm, Ph.D., and colleagues explored how therapy-induced senescence impacts the therapeutic response of melanoma. Using mouse models, the researchers assessed gene […]

Investigators find clues to melanoma treatment resistance

Friday, October 30th, 2015

Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway. In recent years, new drugs have been approved that target the BRAF/MAPK […]

New type of trial shows promise for several cancers

Monday, August 24th, 2015

Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation. The new clinical trial showed promising results in […]

Next Page »